Medical News

RSS

Mimetogen initiates MIM-D3 Phase II clinical trial for dry eye disease

Mimetogen Pharmaceuticals Inc., a clinical-stage biotechnology company focused on developing novel small molecule compounds that mimic the effects of neurotrophins, today announced that it has initiated the first human clinical trial evaluating MIM-D3, a mimetic of nerve growth factor (NGF), in a Phase II clinical trial in patients with moderate to severe dry eye disease. MIM-D3 is a small cyclic peptidomimetic of NGF, a naturally occurring protein in the eye that is responsible for the maintenance of corneal nerves and epithelium, mucin and tear production.

22 Nov 2010

UAHC first quarter revenues increase 20.3% to $2.1 million

United American Healthcare Corporation today announced financial results for the Company's fiscal first quarter ended Sept. 30, 2010, which included higher revenues and improved bottom line results.

22 Nov 2010

Profil Institute expands capabilities to detect cardiac safety signals in diabetes and obesity clinical trials

Profil™ Institute for Clinical Research, Inc., a company specializing in early phase clinical trials for diabetes and obesity, announced today the expansion of its capabilities for cardiac safety and cardiovascular efficacy studies in the company's early phase diabetes and obesity clinical trials.

22 Nov 2010

Pfizer subsidiary extends tender offer for King acquisition

Pfizer Inc. today announced that its wholly-owned subsidiary, Parker Tennessee Corp., has extended the expiration date of its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. for $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes.

22 Nov 2010

Grifols launches Flebogamma 10% DIF intravenous immune globulin in the U.S.

Grifols today announced availability of its recently approved Flebogamma® 10% DIF intravenous immune globulin. Grifols is a global healthcare company specializing in bioscience medicines derived from human plasma. Approval from the US Food and Drug Administration (FDA) for Flebogamma® 10% DIF was obtained in July 2010 and final approval in Europe is expected before the end of the year. Today's announcement signals widespread product availability to the US market.

22 Nov 2010

Cyberonics second quarter net sales increase 17% to $47.5 million

Cyberonics, Inc. today announced results for the quarter ended October 29, 2010.

22 Nov 2010

Medisafe 1 Technologies to develop new medical locking devices for intravenous administration

Medisafe 1 Technologies Corp., a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that that the company's board of directors has approved the research and development of two new medical locking device products.

22 Nov 2010

$S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies$

S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies

S*BIO Pte Ltd today announced that a fourth novel, potential best-in-class compound discovered and developed by S*BIO has entered a Phase 1 clinical trial. The initiation of the study for S*BIO's oral multi-kinase inhibitor, SB1317 or TG02, in patients with advanced/refractory hematologic malignancies has triggered a payment from S*BIO's development and commercialization partner for the program, Tragara Pharmaceuticals.

22 Nov 2010

Medworxx Bed Optimization System goes live across St. Michael's Hospital

Medworxx Inc., provider of healthcare solutions for patient flow, compliance and education, announced today that St. Michael's Hospital is now live on the Medworxx Bed Optimization System (BOS). Medworxx BOS is now live across St. Michael's Hospital, helping to manage 460 beds.

22 Nov 2010

IsoRay to sell $2.25 million in common stock

IsoRay Inc. has entered a securities purchase agreement with an investor to sell $2.25 million in common stock with the potential of $2,075,000 additional funding through two subsequent short term warrant tranches of 90 days and 180 days assuming an average exercise price of $1.40 and that all Series A and B warrants are exercised. Additional funding will occur if Series C or D warrants are exercised.

22 Nov 2010

Agilent's GeneSpring Bioinformatics Solution integrated with GeneGo's MetaCore

GeneGo, Inc., a leading provider of databases, software and services in systems biology and chemistry, and Agilent Technologies, Inc., the world's premier measurement company and a technology leader in chemical analysis, life sciences, electronics and communications, announced today that they have integrated Agilent's GeneSpring Bioinformatics Solution with MetaCore.

22 Nov 2010

BioNeutral signs 'Stand Still' agreement with DFB

BioNeutral Group, Inc., a specialty technology-based life science company, today announced it has signed a "Stand Still" agreement with a leading pharmaceutical company, DFB Pharmaceuticals, Inc. (DFB).

From Evident Corporation - Life Sciences 22 Nov 2010

Bacterin secures $8 million financing from WTI

Bacterin International Holdings, Inc., a creator and developer of revolutionary bone graft material and anti-infective coatings for medical applications, today announced that it has secured an asset based lending facility of up to $8.0 million from Western Technology Investment, and has received approximately $980,000 through the exercise of warrants for a total of approximately $9 million potentially available for the Company's use.

22 Nov 2010

Spectral enters distribution agreement with Toray to market TORAYMYXIN in Canada

Spectral Diagnostics Inc., today announced that it has signed a long-term, exclusive distribution agreement with Toray Industries, Inc. and Toray Medical Co., Ltd. of Japan (collectively "Toray") to market and sell Toraymyxin™ in Canada. Toraymyxin™ is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. This product and Spectral's EAA™ diagnostic, which measures endotoxin and identifies patients for treatment, are already approved for sale by Health Canada.

22 Nov 2010

Parental divorce during childhood linked to stroke in adulthood

Children who experience a parental divorce are over twice as likely to suffer a stroke at some point in their lives, according to new research presented in New Orleans at The Gerontological Society of America's (GSA) 63rd Annual Scientific Meeting.

22 Nov 2010

First Edition: November 22, 2010

Today's headlines offer a range of health policy stories, including more reports on deficit reduction issues, the continuing politics swirling around the health law repeal effort and employers' soaring health care costs.

22 Nov 2010

DaVita announces meal planning tool for dialysis patients

DaVita Inc., a leading provider of kidney care services for those diagnosed with end stage renal disease (ESRD) and chronic kidney disease (CKD), offers patients with very restricted diets an easy to use meal planning tool and recipes for their favorite Thanksgiving dinners at DaVita.com.

22 Nov 2010

Medisafe 1 presents barcoded syringe locking device at Medica 2010 Conference

Medisafe 1 Technologies Corp., a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company's exhibition of its barcoded syringe locking device generated overwhelming interest at the annual Medica 2010 Conference in Dusseldorf Germany, held November 16-19.

22 Nov 2010

Interim results from H.P. Acthar Gel study in patients with advanced diabetic nephropathy

On November 20 at the American Society of Nephrology 43rd Annual Meeting, interim results presented from an ongoing, randomized prospective study conducted independently by James A. Tumlin, MD, at the University of Tennessee College of Medicine Chattanooga indicated that 9 of 15 patients (60%) with advanced diabetic nephropathy who are currently enrolled in the study and have completed or are still undergoing a six month course of treatment with H.P. Acthar ® Gel have exhibited a clinically significant decrease in proteinuria and achieved stabilized renal function.

22 Nov 2010

NASDAQ issues second letter to A.P. Pharma

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more.

22 Nov 2010